CAS
NVCR icon

Coppell Advisory Solutions’s NovoCure NVCR Stock Holding History

Coppell Advisory Solutions’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-76
Closed -$2.29K – 1343
2024
Q4 		$2.29K Sell
76
-1,048
-93% -$22.2K ﹤0.01% 1512
2024
Q3 		$17.5K Buy
1,124
+214
+24% +$3.88K ﹤0.01% 917
2024
Q2 		$15.6K Buy
+910
New +$16K ﹤0.01% 873

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Coppell Advisory Solutions's NVCR Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 76 shares — an estimated $2.29K sold.

Coppell Advisory Solutions first reported a position in NVCR in Q2 2024 and held it in 3 quarters. The position peaked at $17.5K in Q3 2024. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 76 NovoCure shares in Q1 2025, an estimated $2.29K.
  • Coppell Advisory Solutions first reported a position in NovoCure in Q2 2024 and held it in 3 quarters.
  • Coppell Advisory Solutions's NovoCure position peaked at $17.5K in Q3 2024.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.